CRINETICS PHARM (CRNX)
(Delayed Data from NSDQ)
$33.91 USD
-1.57 (-4.43%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $34.01 +0.10 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Crinetics Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CRNX 33.91 -1.57(-4.43%)
Will CRNX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Other News for CRNX
20 Day Moving Average Support appears for CRNX after 4.43% move
Interesting CRNX Put And Call Options For November 21st
CRNX forms MACD Bullish Signal Line Cross on September 19
Is CRNX positioned for a breakdown? MACD Bearish Signal Line Cross shows up after gaining 0.29%
The technical outlook for CRNX is unchanged after it rises 0.98% on September 16